Tamsulosin Hydrochloride Capsule
Product Images NDC 71335-1784

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 71335-1784). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351784)

Label for Tamsulosin HCl 0.4 mg capsule, an oral prescription drug packaged by Bryant Ranch Prepack in Burbank, CA. The label indicates comparison to Flomax 0.4 mg capsule by Aurobindo Pharma Limited. It references a package size of 30 capsules and includes storage instructions and a barcode.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

Line graph depicting mean plasma concentrations of Tamsulosin Hydrochloride over time after a single 0.4 mg oral dose under fasted and fed conditions in eight subjects. The x-axis shows time in hours (0 to 36), and the y-axis shows plasma concentration in ng/mL (0 to 25). The fasted condition line peaks higher and earlier than the fed condition line.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change over time in symptom scores across 13 weeks of treatment. The graph compares three treatments: 0.8 mg dosage, 0.4 mg dosage, and placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows mean change from baseline. The chart includes sample sizes for each time point and uses distinct markers for each treatment group.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change on the vertical axis and duration of treatment in weeks on the horizontal axis. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with sample sizes noted at different time points. The 0.8 mg and 0.4 mg treatments show greater mean reductions over time compared to placebo.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec over treatment duration in weeks. It compares three treatment groups: 0.8 mg, 0.4 mg, and placebo, with mean change values increasing most for the 0.8 mg and 0.4 mg doses and remaining lower for placebo. Sample sizes are noted below the x-axis for each time point.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2,' showing mean change in urine flow rate over treatment duration in weeks. It compares four groups: 0.8 mg dose, 0.4 mg dose, and placebo, each represented by different symbols and lines. The x-axis represents treatment duration (weeks) and the y-axis mean change in flow rate (mL/sec).*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing the molecular formula with distinct functional groups including methoxy, sulfonamide, and ethoxy phenyl rings, and the hydrochloride salt form indicated by HCl.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.